283 related articles for article (PubMed ID: 7059060)
1. Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion.
Legha SS; Benjamin RS; Mackay B; Ewer M; Wallace S; Valdivieso M; Rasmussen SL; Blumenschein GR; Freireich EJ
Ann Intern Med; 1982 Feb; 96(2):133-9. PubMed ID: 7059060
[TBL] [Abstract][Full Text] [Related]
2. Doxorubicin cardiotoxicity in children: reduced incidence of cardiac dysfunction associated with continuous-infusion schedules.
Berrak SG; Ewer MS; Jaffe N; Pearson P; Ried H; Zietz HA; Benjamin RS
Oncol Rep; 2001; 8(3):611-4. PubMed ID: 11295089
[TBL] [Abstract][Full Text] [Related]
3. Detection of doxorubicin cardiotoxicity in patients with sarcomas by indium-111-antimyosin monoclonal antibody studies.
Carrió I; Lopez-Pousa A; Estorch M; Duncker D; Berná L; Torres G; de Andrés L
J Nucl Med; 1993 Sep; 34(9):1503-7. PubMed ID: 8355070
[TBL] [Abstract][Full Text] [Related]
4. High-dose infusional doxorubicin and cyclophosphamide: a feasibility study of tandem high-dose chemotherapy cycles without stem cell support.
Morgan RJ; Doroshow JH; Venkataraman K; Chang K; Raschko J; Somlo G; Leong L; Tetef M; Shibata S; Hamasaki V; Margolin K; Forman S; Akman S; Coluzzi P; Ahn C; Weiss L; Gadgil U; Harrison J
Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2337-45. PubMed ID: 9815632
[TBL] [Abstract][Full Text] [Related]
5. Reduced cardiotoxicity of doxorubicin by a 6-hour infusion regimen. A prospective randomized evaluation.
Shapira J; Gotfried M; Lishner M; Ravid M
Cancer; 1990 Feb; 65(4):870-3. PubMed ID: 2297656
[TBL] [Abstract][Full Text] [Related]
6. A prospective randomized trial of adjuvant chemotherapy with bolus versus continuous infusion of doxorubicin in patients with high-grade extremity soft tissue sarcoma and an analysis of prognostic factors.
Casper ES; Gaynor JJ; Hajdu SI; Magill GB; Tan C; Friedrich C; Brennan MF
Cancer; 1991 Sep; 68(6):1221-9. PubMed ID: 1873773
[TBL] [Abstract][Full Text] [Related]
7. The use of cardiac biopsy to demonstrate reduced cardiotoxicity in AIDS Kaposi's sarcoma patients treated with pegylated liposomal doxorubicin.
Berry G; Billingham M; Alderman E; Richardson P; Torti F; Lum B; Patek A; Martin FJ
Ann Oncol; 1998 Jul; 9(7):711-6. PubMed ID: 9739435
[TBL] [Abstract][Full Text] [Related]
8. Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site Group.
Seymour L; Bramwell V; Moran LA
Cancer Prev Control; 1999 Apr; 3(2):145-59. PubMed ID: 10474762
[TBL] [Abstract][Full Text] [Related]
9. ICRF-187 permits longer treatment with doxorubicin in women with breast cancer.
Speyer JL; Green MD; Zeleniuch-Jacquotte A; Wernz JC; Rey M; Sanger J; Kramer E; Ferrans V; Hochster H; Meyers M
J Clin Oncol; 1992 Jan; 10(1):117-27. PubMed ID: 1727913
[TBL] [Abstract][Full Text] [Related]
10. Clinical and pharmacologic investigation of the effects of alpha-tocopherol on adriamycin cardiotoxicity.
Legha SS; Wang YM; Mackay B; Ewer M; Hortobagyi GN; Benjamin RS; Ali MK
Ann N Y Acad Sci; 1982; 393():411-8. PubMed ID: 6959564
[TBL] [Abstract][Full Text] [Related]
11. Decreased cardiac toxicity of doxorubicin administered by continuous intravenous infusion in combination chemotherapy for metastatic breast carcinoma.
Hortobagyi GN; Frye D; Buzdar AU; Ewer MS; Fraschini G; Hug V; Ames F; Montague E; Carrasco CH; Mackay B
Cancer; 1989 Jan; 63(1):37-45. PubMed ID: 2910423
[TBL] [Abstract][Full Text] [Related]
12. Phase II clinical and pharmacological study of pirarubicin in combination with 5-fluorouracil and cyclophosphamide in metastatic breast cancer.
Dhingra K; Frye D; Newman RA; Walters R; Theriault R; Fraschini G; Smith T; Buzdar A; Hortobagyi GN
Clin Cancer Res; 1995 Jul; 1(7):691-7. PubMed ID: 9816034
[TBL] [Abstract][Full Text] [Related]
13. Feasibility and pharmacokinetic study of infusional dexrazoxane and dose-intensive doxorubicin administered concurrently over 96 h for the treatment of advanced malignancies.
Chow WA; Synold TW; Tetef ML; Longmate J; Frankel P; Lawrence J; Al-Khadimi Z; Leong L; Lim D; Margolin K; Morgan RJ; Raschko J; Shibata S; Somlo G; Twardowski P; Yen Y; Doroshow JH
Cancer Chemother Pharmacol; 2004 Sep; 54(3):241-8. PubMed ID: 15173955
[TBL] [Abstract][Full Text] [Related]
14. Doxorubicin administration by continuous infusion is not cardioprotective: the Dana-Farber 91-01 Acute Lymphoblastic Leukemia protocol.
Lipshultz SE; Giantris AL; Lipsitz SR; Kimball Dalton V; Asselin BL; Barr RD; Clavell LA; Hurwitz CA; Moghrabi A; Samson Y; Schorin MA; Gelber RD; Sallan SE; Colan SD
J Clin Oncol; 2002 Mar; 20(6):1677-82. PubMed ID: 11896119
[TBL] [Abstract][Full Text] [Related]
15. Adriamycin therapy by continuous intravenous infusion in patients with metastatic breast cancer.
Legha SS; Benjamin RS; Mackay B; Yap HY; Wallace S; Ewer M; Blumenschein GR; Freireich EJ
Cancer; 1982 May; 49(9):1762-6. PubMed ID: 7074581
[TBL] [Abstract][Full Text] [Related]
16. [Continuous venous infusion in cancer chemotherapy].
Ota K
Gan To Kagaku Ryoho; 1985 Apr; 12(4):798-805. PubMed ID: 2580486
[TBL] [Abstract][Full Text] [Related]
17. Protective effect of the bispiperazinedione ICRF-187 against doxorubicin-induced cardiac toxicity in women with advanced breast cancer.
Speyer JL; Green MD; Kramer E; Rey M; Sanger J; Ward C; Dubin N; Ferrans V; Stecy P; Zeleniuch-Jacquotte A
N Engl J Med; 1988 Sep; 319(12):745-52. PubMed ID: 3137469
[TBL] [Abstract][Full Text] [Related]
18. Cardiac safety of pegylated liposomal doxorubicin (Doxil/Caelyx) demonstrated by endomyocardial biopsy in patients with advanced malignancies.
Gabizon AA; Lyass O; Berry GJ; Wildgust M
Cancer Invest; 2004; 22(5):663-9. PubMed ID: 15581046
[TBL] [Abstract][Full Text] [Related]
19. Weekly doxorubicin versus doxorubicin every 3 weeks in cyclophosphamide, doxorubicin, and cisplatin chemotherapy for non-small cell lung cancer.
Umsawasdi T; Valdivieso M; Booser DJ; Barkley HT; Ewer M; MacKay B; Dhingra HM; Murphy WK; Spitzer G; Chiuten DF
Cancer; 1989 Nov; 64(10):1995-2000. PubMed ID: 2553235
[TBL] [Abstract][Full Text] [Related]
20. Prevention of doxorubicin-induced congestive heart failure by continuous intravenous infusion in multiple myeloma; a case report and review of the literature.
Lieverse RJ; Ossenkoppele GJ
Neth J Med; 1991 Feb; 38(1-2):33-4. PubMed ID: 2030807
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
